Interpretation of Pharmacovigilance Disproportionality Analyses
Clinical Pharmacology & Therapeutics · 2023-10 · 114 (4) · 745-746
DOI: 10.1002/cpt.2951 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 30.05.2023. Verfasst von Charles Khouri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pharmacovigilance Unit, Grenoble Alpes University Hospital, Grenoble, France.
- Inserm U1300, HP2 Laboratory, Univ. Grenoble Alpes, Grenoble, France.
- Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- INSERM, BPH, U1219, Team AHeaD, Univ. Bordeaux, Bordeaux, France.
- Pôle de Santé Publique, Service de Pharmacologie Médicale, CHU de Bordeaux, Bordeaux, France.
ORCID-Profile: Charles Khouri, Emanuel Raschi
Zitieren
APA
Khouri, C., Fusaroli, M., Salvo, F., & Raschi, E. (2023). Interpretation of Pharmacovigilance Disproportionality Analyses. Clinical Pharmacology & Therapeutics, 114(4), 745-746. https://doi.org/10.1002/cpt.2951
Vancouver
Khouri C, Fusaroli M, Salvo F, Raschi E. Interpretation of Pharmacovigilance Disproportionality Analyses. Clinical Pharmacology & Therapeutics. 2023;114(4):745-746. doi:10.1002/cpt.2951
BibTeX
@article{Khouri2023,
author = {Khouri, Charles and Fusaroli, Michele and Salvo, Francesco and Raschi, Emanuel},
title = {Interpretation of Pharmacovigilance Disproportionality Analyses},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
volume = {114},
number = {4},
pages = {745--746},
doi = {10.1002/cpt.2951}
}
EUVIMED